mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
European journal of nuclear medicine and molecular imaging
View this publicationEuropean journal of nuclear medicine and molecular imaging
View this publicationClinical research in cardiology : official journal of the German Cardiac Society
View this publicationClinical research in cardiology : official journal of the German Cardiac Society
View this publicationFrontiers in genetics
View this publicationZeitschrift fur Orthopadie und Unfallchirurgie
View this publicationCell reports methods
View this publicationSTAR protocols
View this publicationCurrent oncology (Toronto, Ont.)
View this publicationViruses
View this publicationMolecular psychiatry
View this publication